Vertiv Holdings Co
Vertiv Holdings Co (VRT) Stock News
The latest VRT headlines and market coverage — 5 recent stories, updated throughout the day.
- Zacks Investment Research·
Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know
Vertex Pharmaceuticals stock declined 3.07% to $506.74 on October 1, 2026, underperforming the broader market gains. Despite positive earnings forecasts with expected EPS growth of 1.25% and revenue growth of 10.43% for the upcoming quarter, the stock has fallen 6.1% over the past month. The company holds a Zacks Rank of #3 (Hold) with a Forward P/E ratio of 27.73, trading at a premium to its industry average.
- Zacks Investment Research·
Vertiv Holdings Co. (VRT) Stock Moves 1.04%: What You Should Know
Vertiv Holdings Co. (VRT) closed at $253.46, up 1.04%, but underperformed its sector over the past month. Analysts expect strong earnings growth of 47.58% YoY with revenue projected at $3.77 billion (+40.79% YoY). The company holds a Zacks Rank #2 (Buy) rating, though it trades at a premium Forward P/E of 37.51 compared to its industry average of 13.48.
- Zacks Investment Research·
Here's Why Vertiv Holdings Co. (VRT) Fell More Than Broader Market
Vertiv Holdings Co. (VRT) declined 1.32% to $234.26 in the latest session, underperforming the broader market. The company is forecasted to report strong earnings growth of 47.58% YoY with revenue expected at $3.77 billion (+40.79% YoY). Despite a Zacks Rank #2 (Buy) rating and positive analyst estimate revisions, the stock trades at a premium valuation with a Forward P/E of 35.5 versus the industry average of 13.88.
- Zacks Investment Research·Neutral
Why Vertiv Holdings Co. (VRT) Dipped More Than Broader Market Today
Vertiv Holdings Co. (VRT) declined 9.61% in recent trading, underperforming the S&P 500. The company maintains a Zacks Rank #2 (Buy) with strong projected earnings growth of 47.58% and revenue growth of 40.27% for the upcoming quarter. However, the stock trades at a premium valuation with a Forward P/E of 43.49 versus its industry average of 13.49.
- Zacks Investment Research·
Why Is Vertex (VRTX) Up 14.4% Since Last Earnings Report?
Vertex Pharmaceuticals reported Q2 2026 earnings that missed EPS estimates ($4.73 vs $4.79 consensus) but beat revenue expectations ($3.33B vs $3.23B consensus). The company raised full-year 2026 revenue guidance to $13.10-$13.20B. However, analyst estimates have trended downward over the past month despite the stock gaining 14.4%. The company received a Zacks Rank #3 (Hold) rating with a VGM Score of D, suggesting in-line returns ahead.